Page 96

Marzo_2017

artículo de revisión 21. Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol 2006; 4: 239-57. 22. Callado LF, Meana JJ, Grau L, Gonzalvo B. Cannabis. En: Bobes J, Casa M, Gutiérrez M, Editores, Manual de Trastornos Adictivos. Madrid, España: Enfoque Editorial; 2011. p. 440-7. 23. Donoghue K, Doody GA, Murray RM, Jones PB, Morgan 366 C, Dazzan P, et al. Cannabis use, gender and age of onset of schizophrenia: data fromthe AESOP study. Psychiatry Res 2014; 215: 528-32. 24. Kapur B, Lala P, Shaw J. Pharmacogenetics of chronic pain management. Clin Biochem 2014; 47: 1169-87. 25. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Brit J Pharmacol 2009; 156: 397-411. 26. Callado LF. Utilización terapéutica de Cannabis. En Arana X, Markez I, Editores, Cannabis: Salud, Legislación y Políticas de Intervención. Madrid, España: Editorial Dykinson; 2006. p. 73-90. 27. Callado LF, Pomposo I, Garibi J. Rimonabant. En: Salazar M, Peralta C, Pastor FJ, Editores, Tratado de Psicofarmacología: Bases y Aplicación Clínica. Madrid, España: Editorial Médica Panamericana; 2009. p. 419- 21. 28. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68: 515-21. 29. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiplesclerosis. Neurology 2005; 65: 812-9. 30. Ware M, Beaulieu P. Cannabinoids for the treatment of pain: an update onrecent clinical trials. Pain Res Manag 2005; 10: 27a-30a. 31. Schuster R, Hoeppner SS, Evins AE, Gilman JM. Early onset marijuana use is associated with learning inefficiencies. Neuropsychology 2016; 30(4): 404-15. 32. Kangas BD, Leonard MZ, Shukla VG, Alapafuja SO, Nikas SP, Makriyannis A, et al. Comparisons of D9-tetrahydrocannabinol and anandamide on a battery of cognition-related behavior in nonhuman primates. J Pharmacol Exp Ther 2016; 357 (1): 125-33. 33. Clark AJ, Lynch ME, Ware M, Beaulieu P, McGilveray IJ, Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 2005; 10: 44a-6a. 34. Wilkie G, Sakr B, Rizack T. Medical marijuana use in oncology: A review. JAMA Oncol 2016; 2 (5): 670-5. Uso terapéutico de cannabis - M. Avello et al 35. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz NL. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther 2011; 90 (6): 844-51. 36. Ellis RJ, Toperoff W, Vaida F, van den BG, Gonzales J, Gouaux B, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34: 672-80. 37. Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182: E694-701. 38. Wallace 1, Schulteis G, Atkinson JH, Wolfson T, Lazzaretto D, Bentley H, et al. Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology 2007; 107: 785-96. 39. Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes. J Pain 2008; 9 (6): 506-21. 40.- Andreae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, et al. Inhaled cannabis for chronic neuropathic pain: A meta-analysis of individual patient data. J Pain 2015; 16 (12): 1221-32. 41. Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013; 33 (2): 195-209. 42. Naftali T, Schleider LRL, Dotan I, Lansky EP, Benjaminov FS, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013; 11: 1276-80. 43. Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2014; 82 (17): 1556-63. 44. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized double blind-placebo-controlled, parallel-group, enriched design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011; 18 (9): 1122-31. 45. Pavisian B, MacIntosh BJ, Szilagyi G, Staines RW, O’Connor P, Feinstein A. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. Neurology 2014; 82 (21): 1879-87. 46. Savage SR, Romero-Sandoval A, Schatman M, Wallace M, Fanciullo G, McCarberg B, et al. Cannabis in pain treatment: clinical and research considerations. J Pain 2016; 17 (6): 654-68. Rev Med Chile 2017; 145: 360-367


Marzo_2017
To see the actual publication please follow the link above